BackBellevue Life Sciences Acquisition - Tradeable Rights - Feb 2028 Overview

Bellevue Life Sciences Acquisition - Tradeable Rights - Feb 2028 Total Assets

Latest total assets for BLACR: $170M.

Get informed when a big investor buys or sells

+ Follow
Total Assets
$172.19M
1.35% YoYΔ $-2.36M vs prior year quarter

Peer average

Loading

Bellevue Life Sciences Acquisition - Tradeable Rights - Feb 2028 Total Assets History

Loading

Bellevue Life Sciences Acquisition - Tradeable Rights - Feb 2028 vs. peers: Total Assets Comparison

Loading

Bellevue Life Sciences Acquisition - Tradeable Rights - Feb 2028 Total Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Bellevue Life Sciences Acquisition - Tradeable Rights - Feb 2028 (BLACR) FAQ

As of the most recent data (March 2026), BLACR shows a total assets of $170M. That compares with $170M in the prior-year period — down 1.4% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, BLACR's total assets is now $170M (was $170M) — a 1.4% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Bellevue Life Sciences Acquisition - Tradeable Rights - Feb 2028 is outperforming or lagging.

Tracking BLACR's total assets over time shows whether Bellevue Life Sciences Acquisition - Tradeable Rights - Feb 2028 is scaling, shrinking, or reshaping that part of the business. The current reading is $170M That compares with $170M in the prior-year period — down 1.4% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this total assets page, Stockcircle has Bellevue Life Sciences Acquisition - Tradeable Rights - Feb 2028's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect total assets (currently $170M) with ownership activity and broader fundamentals.